KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Halozyme Therapeutics (HALO) over the last 17 years, with Q4 2025 value amounting to $119.8 million.

  • Halozyme Therapeutics' Shares Outstanding (Weighted Average) fell 550.91% to $119.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $119.8 million, marking a year-over-year decrease of 550.91%. This contributed to the annual value of $119.8 million for FY2025, which is 550.91% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $119.8 million for Q4 2025, which was down 550.91% from $120.6 million recorded in Q3 2025.
  • Halozyme Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $142.5 million during Q2 2021, with a 5-year trough of $119.8 million in Q4 2025.
  • Over the past 5 years, Halozyme Therapeutics' median Shares Outstanding (Weighted Average) value was $133.1 million (recorded in 2023), while the average stood at $132.0 million.
  • In the last 5 years, Halozyme Therapeutics' Shares Outstanding (Weighted Average) surged by 433.1% in 2021 and then tumbled by 598.84% in 2024.
  • Over the past 5 years, Halozyme Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $140.6 million in 2021, then decreased by 2.7% to $136.8 million in 2022, then dropped by 3.59% to $131.9 million in 2023, then dropped by 3.87% to $126.8 million in 2024, then decreased by 5.51% to $119.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $119.8 million for Q4 2025, versus $120.6 million for Q3 2025 and $122.3 million for Q2 2025.